EARNEST Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

EARNEST Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-74	Closed	-$6.55K	–	393
2023 Q3	$6.55K	Hold	74	–	–	﹤0.01%	727
2023 Q2	$6.41K	Hold	74	–	–	﹤0.01%	737
2023 Q1	$7.2K	Hold	74	–	–	﹤0.01%	694
2022 Q4	$7.66K	Hold	74	–	–	﹤0.01%	675
2022 Q3	$6K	Hold	74	–	–	﹤0.01%	704
2022 Q2	$6K	Hold	74	–	–	﹤0.01%	728
2022 Q1	$6K	Hold	74	–	–	﹤0.01%	770
2021 Q4	$7K	Hold	74	–	–	﹤0.01%	757
2021 Q3	$6K	Hold	74	–	–	﹤0.01%	781
2021 Q2	$6K	Hold	74	–	–	﹤0.01%	788
2021 Q1	$6K	Hold	74	–	–	﹤0.01%	762
2020 Q4	$6K	Hold	74	–	–	﹤0.01%	745
2020 Q3	$6K	Hold	74	–	–	﹤0.01%	686
2020 Q2	$9K	Hold	74	–	–	﹤0.01%	581
2020 Q1	$6K	Hold	74	–	–	﹤0.01%	610
2019 Q4	$6K	Hold	74	–	–	﹤0.01%	699
2019 Q3	$5K	Hold	74	–	–	﹤0.01%	732
2019 Q2	$6K	Hold	74	–	–	﹤0.01%	693
2019 Q1	$7K	Hold	74	–	–	﹤0.01%	641
2018 Q4	$6K	Hold	74	–	–	﹤0.01%	649
2018 Q3	$7K	Hold	74	–	–	﹤0.01%	654
2018 Q2	$7K	Hold	74	–	–	﹤0.01%	649
2018 Q1	$6K	Hold	74	–	–	﹤0.01%	672
2017 Q4	$7K	Buy	+74	New	+$6.43K	﹤0.01%	627
2017 Q1	–	Sell	-74	Closed	-$6K	–	330
2016 Q4	$6K	Buy	+74	New	+$6.36K	﹤0.01%	622

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EARNEST Partners's BMRN Position: Q4 2023 in Review

EARNEST Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 74 shares — an estimated $6.55K sold.

EARNEST Partners first reported a position in BMRN in Q4 2016 and held it in 25 quarters. The position peaked at $9K in Q2 2020. 548 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

EARNEST Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 74 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $6.55K.
EARNEST Partners first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 25 quarters.
EARNEST Partners's BioMarin Pharmaceuticals position peaked at $9K in Q2 2020.
548 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.